Amgen, Inc. will be keenly awaiting an opinion from the EU regulator this week as to whether sotorasib, its highly innovative treatment for non-small cell lung cancer (NSCLC), should be approved for EU-wide marketing.
Sotorasib, which is already approved in the US under the brand name Lumakras, is the first therapy to target the...








